{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:14:14Z","timestamp":1790648054391,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate availability of spirometry and symptom data in the Clinical Practice Research Datalink (United Kingdom) to assess COPD severity using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 definition and comparing it with an algorithm used in other studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a descriptive, noninterventional, secondary database cohort study of patients with COPD aged 40\u00a0years or older, who initiated treatment with specific COPD medications. Patients were classified according to COPD severity (1) in GOLD 2016 \u201cABCD\u201d categories based on symptoms (Medical Research Council dyspnea grade, COPD Assessment Test, breathlessness), percent predicted FEV1, and exacerbation history and (2) as mild, moderate, severe, or very severe based on treatment and exacerbation history.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 63\u00a0900 patients with COPD aged 40\u00a0years or older that were new users of 1 or more COPD medication of interest. Percent predicted FEV1 was available for 80.9% of patients; symptoms for 75.6% of patients. Classification into GOLD 2016 ABCD categories was possible for 75.6% of the patients. The GOLD 2016 ABCD definition classified more patients under the high\u2010risk categories (22.1%, A; 18.8%, B; 21.3%, C; 37.9%, D) than did the adapted algorithm (7.9%, mild; 48.6%, moderate; 42.1%, severe; 1.4%, very severe).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using our adaptation of the GOLD 2016 COPD severity classification, the information in the Clinical Practice Research Datalink allowed us to ascertain COPD severity in approximately 75% of patients with COPD. Algorithms that include medication use tend to misclassify patients with the extreme COPD severity categories.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4448","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T04:09:53Z","timestamp":1525838993000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD)"],"prefix":"10.1002","volume":"28","author":[{"given":"Cristina","family":"Rebordosa","sequence":"first","affiliation":[{"name":"RTI Health Solutions  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estel","family":"Plana","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Aguado","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Thomas","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Park  NC Raleigh USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garc\u00eda-Gil","sequence":"additional","affiliation":[{"name":"AstraZeneca  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-3691","authenticated-orcid":false,"given":"Susana","family":"Perez\u2010Gutthann","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Castellsague","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"GOLD.Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease (2017 report). Global Initiative for Chronic Obstructive Lung Disease 2017.http:\/\/goldcopd.org\/gold\u20102017\u2010global\u2010strategy\u2010diagnosis\u2010management\u2010prevention\u2010copd\/(accessed 27 December 2017)."},{"key":"e_1_2_8_3_1","unstructured":"GOLD.Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease (2016 report). Global Initiative for Chronic Obstructive Lung Disease 2016.http:\/\/goldcopd.org\/gold\u2010reports\u20102016\/(accessed 20 December 2016)."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021235123382"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-006-9066-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.6.1890"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2367"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.10.004"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3132\/pcrj.2008.00024"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_8_11_1","unstructured":"QuanjerPH StanojevicS ColeTJ et al.GLI\u20102012 regression equations and lookup tables [Global Lung Initiative ERS Task Force (TF\u20102009\u201003) equations]. 07 April2013.http:\/\/www.ers\u2010education.org\/guidelines\/global\u2010lung\u2010function\u2010initiative\/tools\/quanjer\u2010gli\u20102012\u2010regression\u2010equations\u2010and\u2010lookup\u2010tables.aspx(accessed 16 February 2016)."},{"key":"e_1_2_8_12_1","unstructured":"ONS.Data Explorer [software]. DC2101EW ethnic group by sex by age. Office for National Stat 24 September2014.https:\/\/www.ons.gov.uk\/help\/localstatistics(accessed 20 December 2016)."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S82064"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085540"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471445428"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00065013"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6779.766"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.5.686.32205"},{"key":"e_1_2_8_19_1","unstructured":"NICE.NICE Quality and Outcomes Framework Indicator: The percentage of patients with COPD (diagnosed on or after 1 April 2011) in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months after entering on to the register (inherited). National Institute for Health and Care Excellence 2015.https:\/\/www.nice.org.uk\/standards\u2010and\u2010indicators\/qofindicators\/the\u2010percentage\u2010of\u2010patients\u2010with\u2010copd\u2010diagnosed\u2010on\u2010or\u2010after\u20101\u2010april\u20102011\u2010in\u2010whom\u2010the\u2010diagnosis\u2010has\u2010been\u2010confirmed\u2010by\u2010post\u2010bronchodilator\u2010spirometry\u2010between\u20103\u2010months\u2010before\u2010and\u201012\u2010months\u2010after\u2010entering\u2010on\u2010to\u2010the\u2010register\u2010nm103(accessed 16 November 2017)."},{"key":"e_1_2_8_20_1","first-page":"212243","article-title":"Is \u2018GOLD\u2019 standard for the management of COPD in clinical practice?","volume":"2012","author":"Yawn BP","year":"2012","journal-title":"Drugs Context"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:31:58Z","timestamp":1694017918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/pds.4448"],"URL":"https:\/\/doi.org\/10.1002\/pds.4448","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"2017-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}